Sign Up Today and Learn More About BlueWillow Biologics Stock
Invest in or calculate the value of your shares in BlueWillow Biologics or other pre-IPO companies through EquityZen's platform.
BlueWillow Biologics Stock (BLUB)
BlueWillow Biologics operates as a clinical-stage privately-held biopharmaceutical company.
About BlueWillow Biologics Stock
Founded
2000
Headquarters
Ann Arbor, MI, US
Industries
Science and Engineering, Health Care, Biotechnology
BlueWillow Biologics operates as a clinical-stage privately-held biopharmaceutical company. It focuses on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. Its platform employs novel oil-in-water nano-droplets for products administered to the skin and nose. The company was founded as a spin-off from the University of Michigan and is headquartered in Ann Arbor, Michigan.
BlueWillow Biologics Press Mentions
Stay in the know about the latest news on BlueWillow Biologics
Herpes simplex virus nanoemulsion vaccines and methods of using the same
patents • Apr 16, 2024
Persistant topical antimicrobial compositions and methods of using the same
patents • Apr 16, 2024
Persistant topical antimicrobial compositions and methods of using the same
patents • Apr 16, 2024
Intranasal polysaccharide conjugate nanoemulsion vaccines and methods of using …
patents • Apr 16, 2024
Nanoemulsion universal influenza vaccine
patents • Apr 16, 2024
BlueWillow Biologics Management
Leadership team at BlueWillow Biologics
Sr. Vice President, Vaccine Research & Development
Ali I. Fattom
Member Of The Board Of Directors
Robert C. Moellering
Join now and verify your accreditation status to gain access to:
- BlueWillow Biologics current valuation
- BlueWillow Biologics stock price
- Available deals in BlueWillow Biologics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in BlueWillow Biologics stock?
Accredited investors can buy pre-IPO stock in companies like BlueWillow Biologics through EquityZen funds. These investments are made available by existing BlueWillow Biologics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell BlueWillow Biologics stock?
Shareholders can sell their BlueWillow Biologics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
